Govt bans export of anti-malarial drug approved for coronavirus prevention by ICMR

Indian Council of Medical Research recommended hydroxychloroquine for treating healthcare workers handling suspected or confirmed coronavirus cases and for those in contact with infected loved ones.

Amid coronavirus outbreak, the government on Wednesday banned export of anti-malarial drug hydroxychloroquine with immediate effect to ensure sufficient availability of the medicine in the domestic market.

Indian Council of Medical Research (ICMR) Director General Balram Bhargava had on Monday recommended the use of hydroxychloroquine for treating healthcare workers handling suspected or confirmed coronavirus cases and also the asymptomatic household contacts of the lab-confirmed cases.

The treatment protocol recommended by the ICMR-constituted National Task Force for COVID-19 has been approved by the Drug Controller General of India (DGCI) for restricted use in emergency situations.

In a notification issued on Wednesday, the Directorate General of Foreign Trade (DGFT), an arm of the commerce ministry which deals with export and import-related matters, said, “The export of hydroxycloroquine and formulations made from hydroxycloroquine is prohibited with immediate effect”.

It, however, said the government will allow export of the medicine on humanitarian grounds on case-to-case basis on the Ministry of External Affairs’ recommendation.

Export will also be permitted from the special economic zones/export oriented units and in cases where the outbound shipment is made to fulfil export obligation under any advance authorisation license issued on or before the date of this notification, which is March 25, 2020.

“Export will be allowed in case of shipments where irrevocable letter of credit has been issued before the date of this notification or in case where full advance payment has been received by the exporter in India against specific shipment, subject to submission of documentary evidence,” DGFT added.